Vaccine Clinical Statement

Draft

<table>
<thead>
<tr>
<th>Date of publication</th>
<th>01 May 2020</th>
</tr>
</thead>
<tbody>
<tr>
<td>Date of implementation</td>
<td>To be announced</td>
</tr>
</tbody>
</table>

This document is a draft SFDA guideline published for comments and suggestions purposes. It is, therefore, subject to alteration and modification and may not be referred to as SFDA guideline until approved by SFDA.
Vaccine Clinical Statement

Draft

Saudi Food & Drug Authority
Drug Sector

Please send your comments or suggestions before June 29, 2020
to:
Drug.comments@sFDA.gov.sa

Please visit SFDA’s website at
for the latest update
Vision and Mission

Vision
To be a leading international science-based regulator to protect and promote public health

Mission
Protecting the community through regulations and effective controls to ensure the safety of food, drugs, medical devices, cosmetics, pesticides and feed
Document Control

<table>
<thead>
<tr>
<th>Version</th>
<th>Author</th>
<th>Date</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Draft</td>
<td>Products Evaluation</td>
<td>28 April 2020</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Executive Directorate</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Table of Content

1. INTRODUCTION........................................................................................................... 6
2. DEFINITIONS...................................................................................................................... 7
3. TYPES OF SUBMISSIONS.................................................................................................. 8
4. CORRELATE OF PROTECTION ...................................................................................... 12
5. VACCINE EXCIPIENTS ................................................................................................... 14
6. REFERENCE....................................................................................................................... 17
1. INTRODUCTION

Vaccines are important and cost-effective interventions that protect public health. All submitted vaccines marketing applications and variations to the Saudi Food and Drug Authority (SFDA) undergo clinical assessments. To ensure efficiency and consistency of submissions, the SFDA issued this statement with the aim of presenting its point of view regarding clinical requirements for vaccines. This statement represents the current thinking of the SFDA regarding the appropriate level of evidence to support vaccines applications. This guidance should be read in conjunction with SFDA guidelines for drug registration, Guidelines for Production and Quality Control of Vaccines (version 2.1) and international vaccines relevant guidelines produced by the World Health Organisation (WHO).
2. DEFINITIONS

• **Immunological correlate of protection (ICP):** An ICP is most commonly defined as a type and amount of immunological response that correlates with vaccine-induced protection against a clinically apparent infectious disease and that is considered predictive of clinical efficacy. In other words, ICP is the type of immune response (antibody, antitoxin antibody or other immune response), and specific level required to provide an immune protection against a specific pathogen.

• **Clinically significant endpoints:** Some vaccines do not have a well-established ICP. Therefore, the vaccine should provide a clinically significant endpoint relating to the vaccine preventable disease.

• **Human challenge study:** It is a type of study where the study participants intentionally challenged with an infectious disease organism. Such studies conducted in the early phase during vaccines development and in some cases to demonstrate the efficacy of the vaccine.

• **Immunogenicity:** The capacity of a vaccine to elicit a measurable immune response.

• **Novel Vaccine:** A vaccine containing new antigenic/adjuvant components that were not used in previously licensed vaccines.

• **Vaccine antigen:** The active ingredient in a vaccine (or generated by a vaccine) against which a specific immune response is elicited.

• **Vaccine adjuvants:** A substances or combinations of substances that are used in conjunction with a vaccine antigen to improve immune response and clinical effectiveness of the vaccine.
3. TYPES OF SUBMISSIONS

3.1. Novel Vaccines (new antigen):

Clinical requirements:
I. Phase I study that assess the product safety.

II. Phase II study: such study is concerned with finding the appropriate dose of the vaccine by comparing different doses (dose ranging study).

III. Phase III study: a well-controlled study to establish superiority (in case of new antigenic component) over placebo or appropriate control arm. Such study will usually be considered by the reviewer as pivotal study for approval.
Establishing efficacy profile should be the main objective of the study; appropriate consideration should be made to different aspects of the study such as power calculations, selection of appropriate endpoint (i.e. ICP or a clinical endpoint), selection of comparative arm, and ensuring means of reducing bias (e.g. randomization, blinding).
Immunogenicity of the product should be measured appropriately by the use of appropriate assays for detecting correlate of protection against targeted antigen/s. The Protocols should predefine the magnitude of the difference between vaccine groups or vaccine and control group that will be regarded as evidence of superiority. The difference should be selected in such a way that it provides some evidence of a potential clinical advantage.
If the vaccine will/might be given simultaneously with other vaccines, appropriate clinical evidence should be provided to ensure absence of vaccines interaction.
IV. Lot-to-Lot Consistency Study using different batches of the vaccine to provide an assessment of manufacturing consistency. In addition to the information provided on the manufacturing process. Whether or not a clinical lot-to-lot consistency trial is conducted, the consistency of manufacturing to the vaccine lots used in clinical trials should be both demonstrated and well documented. The lots used in clinical trials should be adequately representative of the formulation intended for marketing.

3.2. **Vaccines with known components or antigens yet developed by a new manufacturer:**

Clinical requirements:

I. Phase I study that assess the vaccine safety.

II. Phase II study: such study is concerned with finding the appropriate dose of the vaccine by comparing different doses (dose ranging study). Robust phase II design with strong statistical analysis, outcome measures and appropriate control may in some cases be used as a proxy for phase III trials. In this instance, the applicant should consider discussing the application with the SFDA.

III. Well-designed Phase III, non-inferiority studies that assess the difference between the new manufactured vaccine and well-established vaccine may be required as pivotal evidence for approval. Such studies should be designed appropriately to allow the detection of differences in terms of safety and efficacy profile. The same consideration of study power, selection of appropriate clinical or ICP endpoint, selection of comparative arm, and ensuring means of reducing bias (e.g. randomization, blinding). In addition, scientifically justified non-inferiority margin should be identified prior starting the study.
IV. Lot-to-Lot Consistency Study using different batches of the vaccine.

3.3. Combination Vaccines

I. Combining antigens that protect against multiple types of infections could result in a negative effect on immune response due to the possibility of interactions between the vaccine components or a negative immune interference effect toward some antigenic component. To weigh the risk and benefits due to such combinations, the applicant should be able to provide justification by citing local or international guidelines and relevant clinical trials.

II. For new candidate vaccines that contain known – and one or more new – antigenic components, it is suggested the application may have a non-inferiority preliminary trials of immune response to each known antigenic components in the new formulation versus separate administrations of known and new antigenic components. It could be useful if a control group received co-administration of known and new antigenic components. The exact design depends on the availability of a single licensed vaccine that contains the known antigenic components and whether more than one licensed vaccine has to be given.

3.4. Major variations (Type II) requirements

I. Any changes in the product composition, e.g. use.

II. Requirements for applications to update seasonal influenza strain:
A TYPE II variation should be submitted, including the new introduced strains according to the WHO recommendations on the composition of influenza virus vaccines in the northern hemisphere.
III. Modifying the age group for already known vaccine

In case of age group modification in a vaccine use, bridging trial is required in variation of new indication submission. The trial design may include comparison between the new claimed age group populations versus the representative population in the previous efficacy trial.

NOTES:

- Selection of comparator arm registered by the SFDA is mandatory unless the comparator is registered by a stringent regulatory authority.
- In some cases, human challenge studies can be used as an efficacy-indicating study or to demonstrate a “proof of concept” during the clinical development of vaccines. Depending on the aim, the clinical phase and the study design will be determined.
- Other non-clinical and quality requirements for vaccine must be met.
4. CORRELATE OF PROTECTION

For some vaccines with known antigenic components, there is established ICP. The following table lists vaccines, analytical tests and the required level of immune response.

<table>
<thead>
<tr>
<th>Vaccine</th>
<th>Test</th>
<th>Level required</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anthrax</td>
<td>Toxin neutralization</td>
<td>1,000 IU/ml</td>
</tr>
<tr>
<td>Diphtheria</td>
<td>Toxin neutralization</td>
<td>0.01–0.1 IU/ml</td>
</tr>
<tr>
<td>Hepatitis A</td>
<td>ELISA</td>
<td>10 mIU/ml</td>
</tr>
<tr>
<td>Hepatitis B</td>
<td>ELISA</td>
<td>10 mIU/ml</td>
</tr>
<tr>
<td>Hib polysaccharides</td>
<td>ELISA</td>
<td>1 _g/ml</td>
</tr>
<tr>
<td>Hib conjugate</td>
<td>ELISA</td>
<td>0.15 _g/ml</td>
</tr>
<tr>
<td>Human papillomavirus</td>
<td>ELISA</td>
<td>ND</td>
</tr>
<tr>
<td>Influenza</td>
<td>HAI</td>
<td>1/40 dilution</td>
</tr>
<tr>
<td>Japanese encephalitis</td>
<td>Neutralization</td>
<td>1/10 dilution</td>
</tr>
<tr>
<td>Lyme disease</td>
<td>ELISA</td>
<td>1,100 EIA U/ml</td>
</tr>
<tr>
<td>Measles</td>
<td>Microneutralization</td>
<td>120 mIU/ml</td>
</tr>
<tr>
<td>Meningococcal</td>
<td>Bactericidal</td>
<td>1/4 (human complement)</td>
</tr>
<tr>
<td>Mumps *</td>
<td>Neutralization</td>
<td>ND</td>
</tr>
<tr>
<td>Pertussis*</td>
<td>ELISA (toxin)</td>
<td>5 units</td>
</tr>
<tr>
<td>Pneumococcus</td>
<td>ELISA; opsonophagocytosis</td>
<td>0.20–0.35 _g/ml (for children); 1/8 dilution</td>
</tr>
<tr>
<td>Polio</td>
<td>Neutralization</td>
<td>1/4–1/8 dilution</td>
</tr>
<tr>
<td>Rabies</td>
<td>Neutralization</td>
<td>0.5 IU/ml</td>
</tr>
<tr>
<td>Rubella</td>
<td>Immunoprecipitation</td>
<td>10–15 mIU/ml</td>
</tr>
<tr>
<td>Disease</td>
<td>Test Method</td>
<td>Endpoint</td>
</tr>
<tr>
<td>-------------------------------</td>
<td>--------------------------</td>
<td>----------</td>
</tr>
<tr>
<td>Rotavirus *</td>
<td>Serum IgA</td>
<td>ND</td>
</tr>
<tr>
<td>Tetanus</td>
<td>Toxin neutralization</td>
<td>0.1 IU/ml</td>
</tr>
<tr>
<td>Smallpox</td>
<td>Neutralization</td>
<td>1/20</td>
</tr>
<tr>
<td>Tick-borne encephalitis</td>
<td>ELISA</td>
<td>125 IU/ml</td>
</tr>
<tr>
<td>Tuberculosis *</td>
<td>Interferon</td>
<td>ND</td>
</tr>
<tr>
<td>Varicella</td>
<td>FAMA gp ELISA</td>
<td>≥1/64 dilution; ≥5 IU/ml</td>
</tr>
<tr>
<td>Yellow fever</td>
<td>Neutralization</td>
<td>1/5</td>
</tr>
</tbody>
</table>

*has a clinically significant endpoint.

Different assays that assess ICP could be used. However, they need to be validated and justified by the applicant.
5. VACCINE EXCIPIENTS

For a variety of reasons, each vaccine requires unique composition of different types of excipients. However, an additional consideration should be taken into account for people known to have an allergy toward a specific vaccine component. Below are some types of vaccine excipients.

Types of excipients

- **Adjuvants**: added for enhance immune response to vaccine antigen, targeting the effector response better and conducting a long-term protection.
- **Preservative**: to prevent contamination.
- **Stabilizer**: to keep the stabilization of the vaccine during transportation and storage conditions such as heat, freeze-drying and breaking down from light exposure.
- **Inactivating Ingredients**: used to kill viruses or inactivate toxins.
- **Antibiotics**: used to prevent contamination by bacteria
- **Cell culture materials**: used to grow the vaccine antigens.
- **Emulsifiers** to hold other ingredients together
- **Buffers**: to keep the vaccine at the right PH (acid/alkaline level)
- **Diluent**: is a liquid used to dilute a vaccine to the proper concentration immediately prior to administration.
- **Solvent**: is a substance that dissolves another substance, creating a solution

Listed below are vaccines excipients included in SFDA reviewed vaccines submissions. This list is advisory only and manufacturers can use any excipients as long as they are scientifically justified.
<table>
<thead>
<tr>
<th>Category</th>
<th>Ingredients</th>
</tr>
</thead>
</table>
| **Adjuvants**  | - Aluminium hydroxide  
                 - Aluminium hydroxide gel  
                 - Aluminium Phosphate Gel  
                 - alpha-Tocopheryl hydrogen succinate                                                                                       |
| **Preservative*| - Thimerosal*  
                 - 2-Phenoxyethanol  
                 - Phenol  
                 - Ethanol anhydrous                                                                                                                   |
| **Stabilizer** | - Gelatin  
                 - Phenol red  
                 - Magnesium chloride hexahydrate  
                 - Monosodium L-Glutamate (Photosensitivity)  
                 - Medium 199 Hanks 10x C without phenol red  
                 - Octoxinol 10  
                 - Sucrose  
                 - Urea                                                                                                                                    |
| **Inactivating Ingredients** | - Formaldehyde  
                 - Formaldehyde solution                                                                                                                                 |
| **Antibiotics** | - Kanamycin Acid Sulphate  
                 - Neomycin Sulphate                                                                                                                      |
| **Cell culture materials** | - Dulbecco's Modified Eagle's Medium                                                                                                                                 |
| **Emulsifiers** | - Polysorbate 80                                                                                                                                 |
| **Buffers**    | - Dipotassium hydrogen Ortho phosphate  
                 - Disodium hydrogen phosphate  
                 - Disodium phosphate dehydrate  
                 - Disodium phosphate dodecahydrate  
                 - Histidine  
                 - Potassium chloride  
                 - Potassium Dihydrogen Ortho phosphate  
                 - Potassium dihydrogen phosphate  
                 - Potassium L-glutamate monohydrate  
                 - Potassium Phosphate Monobasic  
                 - Sodium chloride  
                 - Sodium dihydrogen phosphate  
                 - Sodium dihydrogen phosphate monohydrate  
                 - Sodium dihydrogen phosphate dehydrate  
                 - Sodium phosphate buffer  
                 - Sodium Phosphate Dibasic  
                 - Calcium chloride dehydrate  
                 - Dihydrated disodium hydrogen phosphate  
                 - Monohydrated sodium dihydrogen phosphate                                                                                      |
<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>PBS Solution</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Diluent</strong></td>
<td></td>
</tr>
<tr>
<td>- Water for injection</td>
<td></td>
</tr>
<tr>
<td>- Concentrated dilution fluid</td>
<td></td>
</tr>
<tr>
<td><strong>Solvent</strong></td>
<td></td>
</tr>
<tr>
<td>- Magnesium sulphate heptahydrate</td>
<td></td>
</tr>
</tbody>
</table>

* Should be reserved to multidose vaccines vials only
6. **REFERENCE**

